X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (757) 757
Publication (48) 48
Book Review (11) 11
Book / eBook (3) 3
Book Chapter (2) 2
Magazine Article (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (559) 559
male (361) 361
female (349) 349
index medicus (327) 327
oximes - adverse effects (252) 252
middle aged (241) 241
oximes (234) 234
adult (222) 222
animals (196) 196
oximes - therapeutic use (190) 190
aged (164) 164
melanoma - drug therapy (138) 138
oximes - administration & dosage (133) 133
imidazoles - adverse effects (126) 126
melanoma (112) 112
pharmacology & pharmacy (104) 104
oximes - pharmacology (98) 98
proto-oncogene proteins b-raf - antagonists & inhibitors (95) 95
skin neoplasms - drug therapy (86) 86
dermatology (83) 83
proto-oncogene proteins b-raf - genetics (83) 83
technetium tc 99m exametazime (82) 82
vemurafenib (81) 81
toxicology (80) 80
dabrafenib (74) 74
mutation (74) 74
imidazoles - therapeutic use (73) 73
imidazoles - administration & dosage (71) 71
organotechnetium compounds (71) 71
rats (71) 71
oncology (69) 69
treatment outcome (66) 66
antineoplastic agents - adverse effects (65) 65
adolescent (64) 64
skin neoplasms - pathology (62) 62
pyridones - adverse effects (61) 61
pyrimidinones - adverse effects (61) 61
dose-response relationship, drug (57) 57
efficacy (57) 57
double-blind method (54) 54
mice (54) 54
antineoplastic combined chemotherapy protocols - adverse effects (53) 53
melanoma - genetics (53) 53
melanoma - pathology (53) 53
time factors (53) 53
metastatic melanoma (52) 52
aged, 80 and over (51) 51
care and treatment (51) 51
protein kinase inhibitors - adverse effects (51) 51
pyridones - administration & dosage (50) 50
pyrimidinones - administration & dosage (50) 50
indoles - adverse effects (49) 49
sulfonamides - adverse effects (49) 49
antineoplastic combined chemotherapy protocols - therapeutic use (48) 48
research (47) 47
clinical trials as topic (45) 45
fluvoxamine (45) 45
tomography, emission-computed, single-photon (45) 45
therapy (44) 44
antineoplastic agents - therapeutic use (42) 42
cancer (42) 42
toxicity (42) 42
braf (41) 41
norgestrel - analogs & derivatives (41) 41
risk factors (41) 41
survival (39) 39
atropine (38) 38
organophosphate poisoning (38) 38
dogs (37) 37
melanoma - secondary (37) 37
radionuclide imaging (37) 37
nerve agents (36) 36
open-label (36) 36
trametinib (36) 36
acetylcholinesterase (35) 35
analysis (35) 35
antidepressive agents - adverse effects (34) 34
oximes - pharmacokinetics (34) 34
pharmacokinetics (34) 34
poisoning (34) 34
metastasis (33) 33
milbemycin oxime (33) 33
oximes - chemistry (33) 33
administration, oral (32) 32
drug therapy (32) 32
health aspects (32) 32
indoles - therapeutic use (32) 32
mutations (32) 32
administration, cutaneous (31) 31
drug therapy, combination (31) 31
improved survival (31) 31
medicine, general & internal (31) 31
protein kinase inhibitors - therapeutic use (31) 31
skin neoplasms - genetics (31) 31
abridged index medicus (30) 30
mek inhibition (30) 30
safety (30) 30
sulfonamides - therapeutic use (30) 30
young adult (30) 30
inhibition (29) 29
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (722) 722
French (15) 15
German (8) 8
Japanese (6) 6
Italian (3) 3
Polish (3) 3
Bulgarian (1) 1
Czech (1) 1
Danish (1) 1
Finnish (1) 1
Russian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the European Academy of Dermatology and Venereology, ISSN 0926-9959, 01/2015, Volume 29, Issue 1, pp. 61 - 68
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 1, pp. 30 - 39
In patients with melanomas containing activating BRAF mutations, the combination of a BRAF inhibitor and a MEK inhibitor improved overall survival, as compared... 
CRITERIA | BRAF-MUTATED MELANOMA | METASTATIC MELANOMA | RAF INHIBITION | MEDICINE, GENERAL & INTERNAL | MEK INHIBITION | ACQUIRED-RESISTANCE | V600E MUTATION | TUMORS | OVERCOME | VEMURAFENIB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Pyridones - administration & dosage | Aged, 80 and over | Adult | Female | Skin Neoplasms - pathology | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Adolescent | Intention to Treat Analysis | Survival Analysis | Sulfonamides - adverse effects | Indoles - therapeutic use | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Patients | Health aspects | Risk factors | Melanoma | Toxicity | Medical treatment | MEK inhibitors | Antitumor activity | Metastasis | Kinases | Cancer therapies | Clinical outcomes | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 19, pp. 1813 - 1823
In patients with surgically resected melanoma, those with BRAF mutations who received 1 year of oral adjuvant therapy with dabrafenib and trametinib had a 53%... 
HIGH-RISK MELANOMA | SURVIVAL | MEDICINE, GENERAL & INTERNAL | INTERFERON-ALPHA-2B | PLACEBO | THERAPY | MEK INHIBITION | PHASE-III | DOUBLE-BLIND | HAZARD | IPILIMUMAB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Adjuvants, Immunologic - adverse effects | Young Adult | Melanoma - genetics | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Imidazoles - therapeutic use | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Double-Blind Method | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Neoplasm Recurrence, Local | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Adolescent | Survival Analysis | Aged | Pyridones - therapeutic use | Melanoma - surgery | Mutation | Neoplasm Staging | Pyridones - adverse effects | Melanoma - mortality | Usage | Relapse | Patient outcomes | Analysis | Melanoma | Adjuvant treatment | Outcome and process assessment (Health Care) | Reports | Drug therapy | Cancer | Diseases | Medical imaging | Oncology | Metastasis | FDA approval | Kinases | Cancer therapies | Survival | Skin cancer | Metastases | Medical prognosis | Immunotherapy | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 18, pp. 1694 - 1703
The combination of a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in patients with metastatic melanoma produced a significantly higher response... 
CELL LUNG-CANCER | METASTATIC MELANOMA | MEDICINE, GENERAL & INTERNAL | EFFICACY | PATHWAY | SAFETY | KINASE | RESISTANCE | DOSE-ESCALATION TRIAL | RAF INHIBITORS | IMPROVED SURVIVAL | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Imidazoles - pharmacokinetics | Fever - chemically induced | Drug Therapy, Combination - adverse effects | Melanoma - genetics | Adult | Female | Imidazoles - therapeutic use | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | MAP Kinase Signaling System - drug effects | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Aged | Pyridones - therapeutic use | Mutation | Pyridones - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Usage | Patient outcomes | Melanoma | Product/Service Evaluations | Research | Antineoplastic agents | Antimitotic agents | Gene mutations | Causes of | Genetic aspects | Dosage and administration | Drug therapy, Combination | Drug therapy | Cell survival | Protein kinase | Skin diseases | MAP kinase | Kinases | Patients | Drug dosages | Fever | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
The Oncologist, ISSN 1083-7159, 07/2017, Volume 22, Issue 7, pp. 823 - 833
Tremendous progress has been made in the clinical landscape of advanced‐stage BRAF V600–mutant melanoma treatment over the past 5 years. Targeted therapies... 
BRAF | Mitogen‐activated protein kinase signaling system | Drug‐related side effects and adverse reactions | Protein kinase inhibitors | Melanoma | Mitogen-activated protein kinase signaling system | Drug-related side effects and adverse reactions | IMPROVED SURVIVAL | PHASE-3 | COMBINATION | COMBINED DABRAFENIB | THERAPY | MEK INHIBITION | ONCOLOGY | DOUBLE-BLIND | COBIMETINIB | BRAF-MUTANT MELANOMA | VEMURAFENIB | Oximes - adverse effects | Humans | Fever - therapy | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Carbamates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Fever - chemically induced | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Benzimidazoles - adverse effects | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Azetidines - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Melanoma and Cutaneous Malignancies
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2014, Volume 371, Issue 20, pp. 1877 - 1888
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2014, Volume 71, Issue 6, pp. 1102 - 1109.e1
Background BRAF inhibitor (BRAFi) and MEK inhibitor (MEKi) frequently cause cutaneous adverse events. Objective We sought to investigate the cutaneous safety... 
Dermatology | cutaneous adverse event | rash | histology | inflammation | therapy | squamous cell carcinoma | squamous cell carcinoma therapy | ACTIVATION | IMPROVED SURVIVAL | OPEN-LABEL | DERMATOLOGY | METASTATIC MELANOMA | MEK INHIBITION | PATHWAY | RESISTANCE | RAF INHIBITORS | MUTATIONS | VEMURAFENIB | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Skin Neoplasms - drug therapy | Follow-Up Studies | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Young Adult | Pyridones - administration & dosage | Carcinoma, Squamous Cell - mortality | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Retrospective Studies | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Kaplan-Meier Estimate | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Azetidines - administration & dosage | Carcinoma, Squamous Cell - drug therapy | Indoles - adverse effects | Melanoma - drug therapy | Piperidines - adverse effects | Adolescent | Sulfonamides - adverse effects | Aged | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Melanoma - mortality | Complications and side effects | Medical colleges | Melanoma
Journal Article
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 07/2017, Volume 28, Issue 7, pp. 1631 - 1639
Background: Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination... 
trametinib | melanoma | durable outcomes | BRAF | metastatic | dabrafenib | MULTICENTER | OPEN-LABEL | COMBINATION | TRIAL | MEK INHIBITION | ONCOLOGY | DOUBLE-BLIND | POOLED ANALYSIS | NIVOLUMAB | IPILIMUMAB | VEMURAFENIB | Skin Neoplasms - drug therapy | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Imidazoles - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Pyridones - administration & dosage | Time Factors | Melanoma - genetics | Skin Neoplasms - mortality | Protein Kinase Inhibitors - pharmacokinetics | Skin Neoplasms - pathology | Double-Blind Method | Drug Administration Schedule | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Disease Progression | Melanoma - secondary | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Original
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9829, pp. 1893 - 1901
Summary Background Dabrafenib is an inhibitor of BRAF kinase that is selective for mutant BRAF. We aimed to assess its safety and tolerability and to establish... 
Internal Medicine | SURVIVAL | IRRADIATION | MEDICINE, GENERAL & INTERNAL | PATHWAY | RAF INHIBITOR RESISTANCE | B-RAF | MUTATIONS | CANCER | BRAF(V600E) | VEMURAFENIB | Oximes - adverse effects | Humans | Middle Aged | Carcinoma, Squamous Cell - chemically induced | Oximes - administration & dosage | Imidazoles - administration & dosage | Male | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Fever - chemically induced | Indoles - administration & dosage | Brain Neoplasms - secondary | Neoplasms - genetics | Antineoplastic Agents - adverse effects | Melanoma - genetics | Adult | Female | Drug Administration Schedule | Imidazoles - adverse effects | Genotype | Treatment Outcome | Skin Neoplasms - chemically induced | Brain Neoplasms - drug therapy | Mutation - genetics | Melanoma - secondary | Neoplasms - drug therapy | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Maximum Tolerated Dose | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Sulfonamides - adverse effects | Sulfonamides - administration & dosage | Antimitotic agents | Complications and side effects | Melanoma | Dosage and administration | Metastasis | Antineoplastic agents | Drug therapy | Clinical trials | Medical research | Chemotherapy | Mutation | Toxicity | Tumors
Journal Article